MedTrace Logo

A Clinical Study With MT-102 in Subjects With Cancer Cachexia

NCT01238107 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2014-09-10

No results posted yet for this study

Summary

A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer

Conditions

  • Cancer Cachexia

Interventions

DRUG

MT-102

BETA BLOCKER

Sponsors & Collaborators

  • Veeda Oncology

    collaborator OTHER

  • Akamis Bio

    lead INDUSTRY

Principal Investigators

  • Kumar n Pradhash, MD · TATA MEMORIAL HOSPITAL , MUMBAI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Germany
  • India
  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238107 on ClinicalTrials.gov